Cutaneous squamous cell carcinoma in two pediatric lung transplant patients on prolonged voriconazole treatment

2014 ◽  
Vol 18 (6) ◽  
pp. E200-E207 ◽  
Author(s):  
Jackson Y. Wong ◽  
Paul Kuzel ◽  
John Mullen ◽  
Dale Lien ◽  
Muhammad Mahmood ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Lung Transplant ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Transplant Patients

scholarly journals Catastrophic Squamous Cell Carcinoma in Lung Transplant Patients Treated with Voriconazole

2010 ◽  
Vol 36 (11) ◽  
pp. 1752-1755 ◽  
Author(s):  
Sherrif F. Ibrahim ◽  
Jonathan P. Singer ◽  
Sarah T. Arron
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Lung Transplant ◽  
Transplant Patients

scholarly journals The incidence of cutaneous squamous cell carcinoma in patients receiving voriconazole therapy for chronic pulmonary aspergillosis

2020 ◽  
Vol 393 (11) ◽  
pp. 2233-2237 ◽  
Author(s):  
Chris Kosmidis ◽  
Anna Mackenzie ◽  
Chris Harris ◽  
Rola Hashad ◽  
Fiona Lynch ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Cox Regression ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Pulmonary Aspergillosis ◽  
Tertiary Referral Centre ◽  
Transplant Patients ◽  
Increased Risk ◽  
Chronic Pulmonary Aspergillosis

Abstract Voriconazole has been associated with cutaneous squamous cell carcinoma (cSCC) in transplant patients but less is known about the risk in less severely immunosuppressed patients. Our aim was to estimate the incidence of cSCC after voriconazole exposure in patients with chronic pulmonary aspergillosis on a background of chronic lung disease. The notes of patients seen at a tertiary referral centre from 2009 to 2019 with chronic pulmonary aspergillosis were reviewed for the diagnosis of cSCC and voriconazole use documented. Among 1111 patients, 668 (60.1%) received voriconazole for longer than 28 days. Twelve patients received a diagnosis of cSCC; nine had used voriconazole. Mean duration of voriconazole use was 36.7 months. The crude incidence rate was 4.88 in 1000 person/years in those who had voriconazole and 2.79 in 1000 patient/years in those who did not receive voriconazole for longer than 28 days. On Cox regression, age (HR 1.09, 95% CI 1.02–1.16, p = 0.01) and male gender (HR 3.97, 95% CI 0.84–18.90, p = 0.082) were associated with cSCC. Voriconazole use was associated with a slightly increased risk, which was not significant (HR 1.35, 95% CI 0.35–5.20, p = 0.659). Voriconazole use beyond 28 days did not lead to a significantly increased risk of cSCC in a large cohort of patients with chronic pulmonary aspergillosis.

Sign in / Sign up

Export Citation Format

Share Document